Evaluate the Complete FcRn Recycling Pathway, not Just Receptor Binding
Traditional FcRn binding assays measure affinity between FcRn and IgG but provide limited information about intracellular trafficking.
The FcRn: IgG Recycling HMEC-1 Cell Pool offers a functional, whole cell-based approach that assesses the complete recycling process in living endothelial cells, helping researchers generate biologically relevant data for therapeutic antibody discovery.
Figure 1. Illustration of FcRn: IgG Recycling HMEC-1 Cell Pool mechanism of IgG FcRn-mediated recycling.
Key Challenges
Most commercially available FcRn assays measure binding affinity only.
While useful, these biochemical assays cannot determine whether an antibody successfully:
- Is internalized
- Undergoes FcRn-mediated intracellular trafficking
- Escapes lysosomal degradation
- And is efficiently recycled back to the cell surface
As a result, they provide only a partial view of antibody behavior.
Applications
- Therapeutic antibody discovery
- Fc engineering
- Antibody optimization
- Biosimilar characterization
- Pharmacokinetic prediction
- IgG half-life studies
- FcRn biology research
 |
Why Choose a Whole Cell-Based Functional Assay? |
||
Gain functional insights that better support therapeutic antibody selection and Fc engineering strategies.
| Product | Description | Product Link |
|---|---|---|
|
Wild-Type ioGlutamatergic Neurons
|
Ready-to-use human iPSC-derived glutamatergic neurons with rapid maturation, high purity and proven reproducibility. | View Product → |
|
MAPT S305N Disease Model
|
Human glutamatergic neurons carrying the MAPT S305N mutation for frontotemporal dementia and tauopathy research. | View Product → |
|
CRISPR-Ready ioGlutamatergic Neurons
|
Ready-to-use neurons engineered for rapid CRISPR knockout, activation or interference studies without stable Cas9 cell lines. |
CRISPR Knockout →
CRISPR Activation → CRISPR Interference → |
Validated Functional Performance
The assay has been validated across multiple therapeutic antibodies representing different biological targets, demonstrating robust performance in diverse antibody development programs.
|
Nivolumab (PD-1) Figure 2. Dose response of Nivolumab pH dependent antibody recycling in FcRn: IgG Recycling HMEC-1 Cell Pool |
Rituximab (CD20)
Figure 3. Dose response of Rituximab pH dependent antibody recycling in FcRn: IgG Recycling HMEC-1 Cell Pool |
Alirocumab (PCSK9)
Figure 4. Dose response of Alirocumab pH dependent antibody recycling in FcRn: IgG Recycling HMEC-1 Cell Pool |
|
Trastuzumab (HER2)
Figure 5 Dose response of Trastuzumab pH dependent antibody recycling in FcRn: IgG Recycling HMEC-1 Cell Pool |
Basiliximab (IL-2Rα)
Figure 6. Dose response of Basiliximab pH dependent antibody recycling in FcRn: IgG Recycling HMEC-1 Cell Pool |
Build Your Complete FcRn Recycling Workflow
Need Technical Advice?
Whether you are establishing a new FcRn assay or optimizing an existing antibody discovery workflow, our scientific specialists can help you identify the most appropriate assay format and supporting reagents for your application.
-
References
Article content created by Tebubio using courtesy materials provided by BPS Bioscience.